We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Two New NGS Panels to Improve Inherited Disease and Cancer Diagnostics

By LabMedica International staff writers
Posted on 14 Jul 2014
Specially developed next generation sequencing (NGS) panels for inherited diseases and cancer have been designed to enhance convenience, efficiency, and effectiveness in diagnosis and screening.

Integrated DNA Technologies (IDT; Coralville, IA, USA) is extending its portfolio of NGS panels with the addition of the xGen Inherited Diseases Panel and the Pan-Cancer Panel. More...
Joining the xGen Acute Myeloid Leukemia (AML) Cancer Panel, IDT now offers multiple panels for deep sequencing.

The xGen Inherited Diseases panel, designed in collaboration with Emory Genetics Laboratory, was created to combine the ease of whole exome sequencing with the low cost of panels. Emory leveraged IDT “Lockdown Probes” to create a library targeting all exons in HGMD (human gene mutation database) listed genes. The creation of this library simplifies workflow and lowers costs, while facilitating rapid sequencing and providing the high coverage levels needed for clinical diagnostic NGS application - one library, many tests.

The xGen Pan-Cancer Panel has been developed based on the findings of TCGA (The Cancer Genome Atlas) network. NGS has enabled the discovery and characterization of gene-specific mutations that have the potential to be tumorogenic, but it also implicates irrelevant genes. A shortlist of significant genes that have been deemed relevant across numerous cancer types, which can be expanded through the inclusion of additional tumor-specific genes, would be extremely valuable to both clinical and research applications. TGCA network has identified 127 significantly mutated genes across 12 tumor types. The Pan-Cancer Panel has been designed to target coding regions in all 127 genes.

Target enrichment enables users to focus their sequencing efforts on specific regions of the genome, providing a cost-effective and reliable alternative to whole genome sequencing, making NGS more accessible. Ibrahim Jivanjee, product manager for NGS at IDT, said, “Having launched our xGen AML Panel last October, we have invested a significant amount of time and resource into the further development of our NGS capabilities. As a rapidly advancing area, next gen sequencing is key to the development of personalized medicine, and these two new panels will aid us in supporting the developing advancements in human health and clinical research.”

All three IDT NGS Panels use xGen Lockdown Probes—120mer oligonucleotides with a 5’ biotin modification. Synthesized individually using the IDT Ultramer synthesis platform, Lockdown Probes incorporate the highest coupling rate currently available, 99.6%, to provide high quality, long oligos. The quality of each capture probe is assessed using electrospray ionization mass spectrometry and even probes with a high GC content can be synthesized.

Related Links:

Integrated DNA Technologies 
xGen Panels



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Candida Glabrata Test
ELIchrom Glabrata
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.